Search hospitals > California > Mountain View

Palo Alto Medical Foundation-Gynecologic Oncology

Claim this profile
Mountain View, California 94040
Global Leader in Ovarian Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Fallopian Tube Cancer
Conducts research for Breast cancer
122 reported clinical trials
8 medical researchers
Photo of Palo Alto Medical Foundation-Gynecologic Oncology in Mountain ViewPhoto of Palo Alto Medical Foundation-Gynecologic Oncology in Mountain ViewPhoto of Palo Alto Medical Foundation-Gynecologic Oncology in Mountain View

Summary

Palo Alto Medical Foundation-Gynecologic Oncology is a medical facility located in Mountain View, California. This center is recognized for care of Ovarian Cancer, Lung Cancer, Breast Cancer, Fallopian Tube Cancer, Breast cancer and other specialties. Palo Alto Medical Foundation-Gynecologic Oncology is involved with conducting 122 clinical trials across 265 conditions. There are 8 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Jorge A. Garcia-Young.

Area of expertise

1Ovarian Cancer
Global Leader
Palo Alto Medical Foundation-Gynecologic Oncology has run 23 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive
2Lung Cancer
Global Leader
Palo Alto Medical Foundation-Gynecologic Oncology has run 22 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage IV

Top PIs

Clinical Trials running at Palo Alto Medical Foundation-Gynecologic Oncology

Lung Cancer
Ovarian Cancer
Esophageal cancer
Uterine Cancer
Pancreatic Carcinoma
Multiple Myeloma
Breast Cancer
Kidney Cancer
Breast cancer
Non-Small Cell Lung Cancer
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Palo Alto Medical Foundation-Gynecologic Oncology?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security